The landscape of cancer care expanded with renewed hope in 2025, as a wave of new and expanded treatment options reached patients. This progress was fueled by pivotal clinical research that led to ten significant drug approvals by the U.S. Food and Drug Administration over the course of the year. These therapies address a broad spectrum of cancers, from common to exceedingly rare, offering new strategies where options were limited. Each approval represents a tangible advance, often allowing patients to receive more effective treatments sooner or providing a path where none existed before.
Among the year's milestones was the first-ever treatment for a rare and stubborn form of ovarian cancer, low-grade serous ovarian cancer, which received accelerated approval in May. For patients with this difficult-to-treat disease, the combination therapy offers a long-awaited targeted approach. Similarly, in February, a new kinase inhibitor arrived for adults battling tenosynovial giant cell tumor, a rare joint tumor. This approval stemmed from an international trial that provides a non-surgical option to control the condition. The momentum continued into autumn with a new oral therapy for advanced breast cancer that has developed resistance to standard hormone treatments, offering a new line of defense for a specific group of patients.
Significant progress was also made in moving effective treatments earlier into a patient's journey, aiming to improve outcomes and reduce side effects. A major step forward came in March for men with metastatic prostate cancer, as a targeted radiopharmaceutical drug was approved for use prior to chemotherapy. This allows patients to benefit from this precise cell-killing radiation sooner, potentially avoiding the tougher side effects of chemo. This theme of earlier intervention was echoed in June for head and neck cancer, where an established immunotherapy was approved for use before and after surgery alongside standard treatments, significantly reducing the risk of the cancer returning.
The year also brought sophisticated new options for blood cancers, particularly for patients who have seen their disease return. In October, a novel menin inhibitor was approved for certain adults and children with acute leukemia marked by a specific genetic mutation, building on its prior approval for a different mutation just a year earlier. December brought a CAR T cell therapy approval for a slow-growing lymphoma, adding a powerful cellular immunotherapy to the arsenal. Furthermore, a new triple-drug combination for follicular lymphoma and a full approval for a targeted immunotherapy in small cell lung cancer, following its earlier conditional approval, provided renewed strategies for patients whose cancers had progressed.
Rounding out the year's achievements was a pivotal first in stomach cancers. In late November, an immunotherapy combined with chemotherapy became the first such treatment approved for use before and after surgery for early-stage gastric and gastroesophageal cancers. This approval, based on a global trial, offers a new standard of care aimed at preventing recurrence after surgery. Together, these ten approvals of 2025 illustrate a relentless and hopeful push in oncology toward more personalized, effective, and timely interventions, changing the outlook for countless patients and their families.